



Disclosures: *Standards of Medical Care in Diabetes—2022*

Diabetes Care 2022;45(Suppl. 1):S256–S258 | <https://doi.org/10.2337/dc22-SDIS>

Committee members disclosed the following financial or other conflicts of interest (COI) covering the period 12 months before December 2021

Member	Employment	Research grant	Other research support	Speakers' bureau/honoraria	Ownership interest	Consultant/advisory board	Other
Professional Practice Committee							
Boris Draznin, MD, PhD (Chair)	University of Colorado Denver, School of Medicine	None	None	None	None	None	eDoctate (unpaid professional education)
Vanita R. Aroda, MD	Brigham and Women's Hospital Faculty, Harvard Medical School	Applied Therapeutics#, Eli Lilly#, Fractyl#, Novo Nordisk#	None	None	Janssen (spouse employee benefits)	Applied Therapeutics#, Novo Nordisk*#, Pfizer, Sanofi	Janssen Pharmaceutical Companies of Johnson & Johnson (spouse Sandip Datta, MD, Senior Director, Translational Sciences, Immunology, May 2020 to present) Consultant/Educational Activities: American College of Cardiology, American Diabetes Association, Cardiometabolic Health Congress, Endocrine Society, Hello Diabetes Academia, PeerView, PeerVoice
George Bakris, MD	University of Chicago Medicine	None	None	None	None	Merck, Novo Nordisk, Bayer, KBP Biosciences, Ionis, Alnylam, AstraZeneca, Quantum Genomics, Horizon, DiaMedica Therapeutics	Editor of <i>American Journal of Nephrology</i>
Gretchen Benson, RDN, LD, CDCES	Minneapolis Heart Institute Foundation	None	None	None	None	None	None
Florence M. Brown, MD	Joslin Diabetes Center, Inc.	Dexcom#†	None	None	None	None	None
RaShaye Freeman, DNP, FNP-BC, CDCES, ADM-BC	HCA Healthcare	None	None	None	None	None	None
Jennifer Green, MD	Duke University Medical Center	Boehringer Ingelheim/ Lilly Alliance*#, Merck*#, Sanofi Lexicon*#, Roche*#	None	None	None	AstraZeneca, Boehringer Ingelheim/ Lilly Alliance*, Novo Nordisk, Pfizer, Hawthorne Effect/ Omada*, AstraZeneca, Jaeb Center for Health Research, Bayer, Sanofi/Lexicon	None

Continued on p. S257

Downloaded from http://diabetesjournals.org/care/article-pdf/45/Supplement_1/S256/636865/dc22sdiss.pdf by guest on 26 March 2023

Member	Employment	Research grant	Other research support	Speakers' bureau/honoraria	Ownership interest	Consultant/advisory board	Other
Elbert Huang, MD, MPH, FACP	University of Chicago	None	None	None	AbbVie* (stockholder)	Twin health, Inc.	Medical Research Analytics and Informatics Alliance—BOD International Geriatric Diabetes Society—BOD
Diana Isaacs, PharmD, BCPS, BC-ADM, CDCES	Cleveland Clinic	None	None	Abbott, Dexcom, Medtronic, Novo Nordisk, Xeris Pharmaceuticals, Bayer	None	Insulet, LifeScan, Sanofi, Lilly, DiabetesWise	None
Scott Kahan, MD, MPH	George Washington University, Milken Institute National Center for Weight and Wellness	None	None	None	None	Vivus, Gelesis, Pfizer, Lilly	(All without compensation) The Obesity Society—BOD Obesity Action Coalition—BOD Endocrine Society—Advocacy and Public Outreach Core Committee
Jose Leon, MD, MPH	National Center for Health in Public Housing	None	None	None	None	None	None
Sarah K. Lyons, MD	Baylor College of Medicine/Texas Children's Hospital	None	None	None	Eli Lilly (parent stockholder)†	None	Unpaid Board Member on Epic's Pediatric Endocrinology Steering Board
Anne L. Peters, MD	Keck School of Medicine of USC	Dexcom#, Insulet#, Donates devices from Abbott Diabetes Care#	None	None	Stock options: Omada Health, Teladoc	Abbott Diabetes Care, Eli Lilly, Medscape*, Novo Nordisk, Zealand, Vertex, AstraZeneca	Special government employee for U.S. Food and Drug Administration
Priya Prahalad, MD, PhD	Stanford Hospital and Clinics Lucile Packard Children's Hospital	None	None	None	None	None	Unpaid Board Member on Epic's Pediatric Endocrinology Steering Board
Jane E.B. Reusch, MD	University of Colorado	None	None	None	None	Medtronic#	None
Deborah Young-Hyman, PhD, CDCES	Behavioral Health & Social Science Research, National Institutes of Health	None	None	None	None	None	None
American College of Cardiology Designated Representatives and Staff (Section 10 "Cardiovascular Disease and Risk Management")							
Sandeep Das, MD, MPH, FACC	University of Texas Southwestern Medical Center	None	None	<i>Circulation</i> (Associate Editor)	None	None	None
Mikhail Kosiborod, MD, FACC	Saint Luke's Mid America Heart Institute	AstraZeneca#, Boehringer Ingelheim#	AstraZeneca#	None	None	Amgen*, Applied Therapeutics#, AstraZeneca*#, Bayer*, Boehringer Ingelheim*, Eli Lilly, Janssen*#, Merck (Diabetes & Cardiovascular)*, Novo Nordisk*#, Sanofi*, Vifor Pharma*#, Esperion Therapeutics	None

Continued on p. S258

Member	Employment	Research grant	Other research support	Speakers' bureau/honoraria	Ownership interest	Consultant/advisory board	Other
American Diabetes Association Staff							
Mindy Saraco, MHA	American Diabetes Association	None	None	None	None	None	None
Malaika I. Hill, MA	American Diabetes Association	None	None	None	None	None	None
Robert A. Gabbay, MD, PhD	American Diabetes Association	None	None	None	None	Onduo*, Lark, Vida Health*	Spouse Christi Gabbay, CHSE, Managing Director, Major Gifts and Philanthropy at American Diabetes Association Endocrinologist, Joslin Diabetes Center (unpaid/volunteer)
Nuha Ali El Sayed, MD, MMSct†	American Diabetes Association	None	None	None	None	Expert, World Health Organization	Endocrinologist, Joslin Diabetes Center (unpaid/volunteer) Chair, Diabetes Education for All (unpaid)

Disclosures may have been identified and/or acquired after the committee members were selected for the Professional Practice Committee. BOD, board of directors. * \geq \$10,000 per year from company to individual. #Grant or contract is to university or other employer. †Disclosure made after committee member began work on the Standards of Care 2022 update. ‡Employed by Joslin Diabetes Center prior to joining the American Diabetes Association in August 2021.